

Gianluca Gaidano, MD, PhD

Gianluca Gaidano is Professor of Hematology at the Medical School of the University of Eastern Piedmont (Universita' del Piemonte Orientale), Novara, Italy. He is also the Director of the Division of Hematology of the Academic Hospital "Maggiore della Carità di Novara", the University Vice-Rector for International Affairs, and the Director of the Medical Biotechnologies Master Degree Program at the University of Eastern Piedmont. He is a member of EHA, ASH, ASCO, AACR, Henry Kunkel Society, SIE and SIES, and a former President of the Italian Society of Experimental Hematology. He is currently a board member of EHA, of the Italian Lymphoma Foundation (FIL), of the Italian Society of Hematology, and of the GIMEMA Working Party on chronic lymphoproliferative disorders. He is currently Chair of the Global Outreach Program of EHA. He has served in the EHA Scientific Program Committee and in the Fellowship and Grant Committee of EHA, and is currently serving in the EHA Education Committee. He started his medical career at the University of Turin, where he received his M.D. (1987) and Ph.D (1991), and became a specialist in Internal Medicine and Hematology. From 1990 to 1994, he was at Columbia University (Dalla-Favera's lab), New York, where he trained in molecular hematology. His research interests relate mainly to the clinical implications of the molecular genetics of lymphoid malignancies, with a particular focus on the development of new diagnostic and prognostic markers as well as targeted treatments for B-cell lymphoma and chronic lymphocytic leukemia (CLL). Using a genomic approach, his research group recently identified several novel genetic alterations predicting poor outcome in CLL. Other fields of interest concern hematologic neoplasias developing in immunodeficient patients. He has contributed to several hematology and oncology textbooks, including the DeVita, Hoffman, and Magrath. He has published and co-authored over 600 scientific articles (H-index 73 according to Scopus, Elsevier), of which a significant number in high-impact journals, including Nature, N Engl J Med, Lancet Oncol, Nature Genetics, Blood, J Exp Med, J Clin Oncol, PNAS, J Natl Cancer Inst, Haematologica, Cancer Res, Clin Cancer Res, Leukemia.